A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

Stopped early · Phase 2

Conditions studied: Corneal Infiltrates

In brief

The purpose of the study is to determine whether Moxidex ophthalmic solution is safe and effective in treating marginal corneal infiltrates.

Key facts

Study ID

NCT00579020

Run by

Alcon Research

People needed

144

Starts

2007-12-01

Expected to finish

2009-02-01

Last updated by the study team

2012-12-05

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of marginal corneal infiltrates of size equal to or less than 1.5mm in diameter, with mild, moderate or severe bulbar conjunctival injection in at least one eye.
• Other protocol-defined inclusion criteria may apply.

You may not qualify if…

• Age related.
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Contact Alcon Call Center at 1-888-451-3937 — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.